Nationwide, Congress, insurers, and others continue to wrestle with the costs of healthcare. What is good for some consumers may be bad for others, and a bipartisan coalition is asking the Trump Administration to consider this while they work on legislation regarding drug pricing. Other actions are
Passing Drug Rebates to Clients, New Cancer Treatments and More
In this week's Innovation Partners BioBlog, we look at how United Health and its pharmacy benefits management arm, OptumRX, are looking to pass rebates to new employer customers to deflect criticism from many fronts. Scott Gottlieb, the FDA Chief, announced he is stepping down, possibly as early as
How Can We Reduce the Cost of Healthcare?
That’s the subject of this week’s Innovation Partners BioBlog. A bipartisan group wishes to delay the health insurance tax by two years. Blue Cross Blue Shield wishes to see ObamaCare subsidies expanded. Meanwhile, consumers aren’t seeing value in value-based care, a finding that surprised
Crucial Meetings on Capitol Hill this Week
Seven CEOs from the world’s largest pharmaceutical companies met with lawmakers on Capitol Hill for what some are calling a potential turning point in the public perception of the industry. The meetings focus on the continued outcry against the rising cost of drugs. For instance, insulin, which has
Payments, Efficacy and Outcomes —This Week in Healthcare News
NCCN Academy for Excellence & Leadership in Oncology School of Pharmaceutical & Biotech Business3.20.19 Orlando, FLLearn about models for successful collaboration in practice management and Health Information Technology Payment, efficacy and outcomes are center stage in this week’s
How Can We Lower the Costs of Healthcare and Drugs?
This week’s Innovation Partners BioBlog explores the ideas, thinking, and policies that shape the debate around lowering the cost of healthcare and drugs. A new study finds that Medicare and Medicaid are better at keeping spending per beneficiary low. The Trump Administration may be putting more
GSK, Anthem, Cancer Drugs in the News
This week’s Innovation Partners BioBlog reports on the accelerated timeline for Anthem’s new PBM as well as GlaxoSmithKline’s move to acquire Merck KGaA cancer immunotherapy. ASCO names treatments for rare cancer as the “Advance of the Year,” and the University of Pittsburgh School of Medicine’s
Medicaid, Medicare, and Oncology in the Spotlight
This week’s Innovation Partners BioBlog looks at changes to California’s Medicaid program that may shake up the current Medi-Cal system. Debate continues on step therapy in Medicare, Part B and Medicare unveiled a new app intended to help people determine what is covered. Oncologists and others